Nucleic acid aptamers in therapeutic anticoagulation

Richard C. Becker; Christopher Rusconi; Bruce Sullenger

doi:10.1160/TH04-12-0790

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 93(06): 1014-1020
DOI: 10.1160/TH04-12-0790

Review Article

Schattauer GmbH

Nucleic acid aptamers in therapeutic anticoagulation

Technology, development and clinical application

Richard C. Becker

¹Cardiovascular Thrombosis Research Center, Center for Genetics and Cellular Therapies, Duke University Medical Center, Durham, North Carolina, USA

,

Christopher Rusconi

²Department of Experimental Surgery, Center for Genetics and Cellular Therapies, Duke University Medical Center, Durham, North Carolina, USA

,

Bruce Sullenger

³Department of Genetics, Center for Genetics and Cellular Therapies, Duke University Medical Center, Durham, North Carolina, USA

› Author Affiliations

Abstract

Summary

The evolution of anticoagulant therapy for the prevention and treatment of thrombotic disorders has progressed at a relatively modest pace considering the scope of the problem and our current understanding of platelet biology, coagulation proteases, and vascular science as they apply to protective haemostasis and pathologic thrombosis. Recent observations, dedicated to cellular-based models of coagulation, provide fundamental constructs, mechanistic clarity, and potentially unparalleled opportunity for accelerating the development and wide-scale clinical use of safe, effective, regulatable and patient-specific therapies. The following review introduces a novel domain of anticoagulant therapy referred to as aptamers (derived from the Latin aptus – to fit), considering their history, development, and potential application in patient care arenas.

Keywords

Aptamers - protein-binding oligonucleotides - anticoagulant therapy

Full Text

References

References
1 Gold L, Polisky B, Uhlenbeck O. et al. Diversity of oligonucleotide functions. Annu Rev Biochem 1995; 64: 763-97.
2 Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249: 505-10.
3 Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346: 818-22.
4 Dausse E, Cazenave C, Rayner B. et al. In vitro selection procedures for identifying DNA and RNA aptamers targeted to nucleic acids and proteins. Methods Mol Biol 2005; 288: 391-410.
5 Rimmele M. Nucleic Acid aptamers as tools and drugs: recent developments. Chembiochem 2003; 4: 963-71.
6 Pieken WA, Olsen DB, Benseler F. et al. Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. Science 1991; 253: 314-7.
7 Beigelman L, McSwiggen JA, Draper KG. et al. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem 1995; 270: 25702-8.
8 Rusconi CP, Yeh A, Lyerly HK. et al. Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost 2000; 84: 841-8.
9 Doudna JA, Cech TR, Sullenger BA. Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proc Natl Acad Sci USA 1995; 92: 2355-9.
10 Lee SW, Sullenger BA. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine acetylcholine receptors from myasthenic antibodies. Nat Biotechnol 1997; 15: 41-5.
11 Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-9.
12 Rusconi CP, Scardino E, Layzer J. et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002; 419: 90-4.
13 Bock LC, Griffin LC, Latham JA. et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992; 355: 564-6.
14 Griffin LC, Tidmarsh GF, Bock LC. et al. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 1993; 81: 3271-6.
15 Li WX, Kaplan AV, Grant GW. et al. A novel nucleotide- based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. Blood 1994; 83: 677-82.
16 DeAnda Jr. A, Coutre SE, Moon MR. et al. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann Thorac Sur 1994; 58: 344-50.
17 Tasset DM, Kubik MF, Steiner W. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J Mol Biol 1997; 272: 688-98.
18 Holland CA, Henry AT, Whinna HC. et al. Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin. FEBS Lett 2000; 484: 87-91.
19 Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. [Review] Arterioscler Thromb Vasc Biol 2003; 23: 17-25.
20 Usman N, Blatt LM. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. [Review] J Clin Invest 2000; 106: 1197-202.
21 Khachigian LM. Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. [Review] J Clin Invest 2000; 106: 1189-95.
22 White R, Rusconi C, Scardino E. et al. Generation of species cross-reactive aptamers using “toggle” SELEX. Mol Ther 2001; 4: 567-73.
23 Yan X, Gao X, Zhang Z. Isolation and characterization of 2'-amino-modified RNA aptamers for human TNF alpha. Genomics Proteomics Bioinformatics 2004; 2: 32-42.
24 Skrypina NA, Savochkina LP, Beabealashvilli RSh. In vitro selection of single-stranded DNA aptamers that bind human pro-urokinase. Nucleosides Nucleotides Nucleic Acids 2004; 23: 891-3.